Seres Therapeutics, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Seres Therapeutics amended its Non-Employee Director Compensation Program effective June 17, 2026. The program provides annual cash retainers ($45,000 base plus committee-specific retainers ranging $5,000–$35,000), with directors able to elect to receive retainers as stock options valued via Black-Scholes. Initial grants are 13,000 shares; annual subsequent grants are 6,500 shares. No specific dollar amounts or participant counts are disclosed in this policy document.
Why this rating
Routine director compensation policy amendment. No material change disclosed; standard governance document relative to $71.9M market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.